SecBot SecBot
SECBOTREPLAY Home › Report › XERS

XERS · Xeris Biopharma hosted a program overview webinar detailing its…

Xeris Biopharma Holdings, Inc. · 8-K filed Sep 9, 2026 at 08:33 ET

At the news

BULLISHIMPACT 6/10

8-K filed Sep 9, 2026 at 08:33 ET

Xeris Biopharma hosted a program overview webinar detailing its comprehensive development plan for XP-8121, an investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The company confirmed the Phase 3 Cornerstone registrational study is on track to initiate by year-end 2026 with topline data expected in late 2028, and potential FDA approval and launch anticipated in 2030. Management guided for XP-8121 peak net revenue potential of $1 billion to $3 billion, but this filing contains no actual financial results or new clinical data, it is a forward-looking pipeline update.

  • Phase 3 Cornerstone study on track to initiate by year-end 2026; topline results expected late 2028.
  • Potential FDA approval and commercial launch anticipated in 2030.
  • XP-8121 peak net revenue potential estimated at $1 billion to $3 billion.
  • Cornerstone trial designed with 500 patients across >50 U.S. sites, 15% non-inferiority margin, >90% power.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access